D. Boral Capital reissued their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock.
Kairos Pharma Trading Down 7.4%
KAPA opened at $0.87 on Tuesday. The firm’s 50 day simple moving average is $1.29 and its two-hundred day simple moving average is $0.97. The company has a market capitalization of $18.04 million, a PE ratio of -2.56 and a beta of 2.02. Kairos Pharma has a 1-year low of $0.40 and a 1-year high of $3.25.
Institutional Trading of Kairos Pharma
A hedge fund recently bought a new stake in Kairos Pharma stock. Armistice Capital LLC acquired a new stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,404,000 shares of the company’s stock, valued at approximately $1,314,000. Armistice Capital LLC owned 10.25% of Kairos Pharma at the end of the most recent reporting period.
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Featured Stories
- Five stocks we like better than Kairos Pharma
- 3 Ways To Invest In Coffee, Other Than Drinking It
- CAVA Stock Looking for Direction After Earnings Miss
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Small AI Stocks Ready to Explode (All Under $20)
- Best Stocks Under $10.00
- After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
